Ontogenetic Market Overview
Ontogenetic Market Size was valued at USD 1.01 Billion in 2023. The Global Ontogenetic industry is projected to grow from USD 1.07 Billion in 2024 to USD 1.87 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.98% during the forecast period (2024 - 2032).
Ontogenetic is a developmental history of an organism, which includes the study of cognitive, physical, social, and emotional development, which can be attributed to experience with the individuals and the environment within the environment. Ontogenetic is a vast subject and continuous research in the field is expanding its applications. Increasing human and animal population is one of the major factors affecting the ontogenetic market growth, positively.
Furthermore, increasing funding for research is one of the major driving factors of the ontogenetic market. Epilepsy is the disorder of a nervous system. According to the last updated report on February 2017 by World Health Organization (WHO), around 50 million people are affected with epilepsy globally, and it affects people of all ages. The report suggests that around 2.4 million people are diagnosed with epilepsy every year globally.
Companies are focusing on merger and also collaborating with universities or academic institutes for further study on ontogenetic. In this regards, in March 2016, Natus Medical Incorporated announced its expansion of neurodiagnostic services into seven new states with the acquisition of the assets of NeuroQuest, LLC. This acquisition helped Natus Medical Incorporated in expanding their network globally and helped to increase the market share. Rapidly changing technology plays an important role in the growth of ontogenetic market. Technological advancement is opening new doors to the ontogenetic research and use.
Governments of different nations have done various developments to encourage research, which is driving the ontogenetic market growth. Increasing adoption of various oncologic practices owing to rising patient population having a nervous disorder. According to the last updated report on February 2017 by the World Health Organization (WHO), annually 30-50 cases are diagnosed per 100 000 people, whereas, in low and middle-income countries, this figure is up to two times higher.
The developed countries are holding major ontogenetic market share owing to the availability of advanced infrastructure, skilled professionals, and high expenditure, but the market is rapidly expanding in emerging countries such as India, China, and Brazil. The research activities in Pacific region, especially, in Australia is increasing and is expected to grow significantly during the forecast period.
Intended Audience
- Ontogenetic Services Providers
- Medical Research Laboratories
- Research and Development Companies
- Market Research and Consulting Service Providers
- Government Policy Makers and Authorities
Segmentations
The ontogenetic market is segmented on the basis of devices, application, and end user.
On the basis of the devices, ontogenetic market is segmented into electroencephalography, magnetoencephalography, and others.
On the basis of the application, ontogenetic market is segmented into developmental biology, developmental psychology, developmental cognitive neuroscience, developmental psychobiology, and others.
On the basis of the end user, ontogenetic market is segmented into research laboratories, academic institutes, and others. Furthermore, the research laboratories are segmented into government research laboratories, independent or private research laboratories, and others.
Regional Analysis
The Americas dominate the ontogenetic market owing to a large amount of money invested in the research and development and clinical trials. The Americas mainly includes North America and South America. North America is the leading regional market, whereas South America ontogenetic market is also growing at a significant rate. The U.S. is the highest revenue generating country within the region.
The European market is the second largest and is expected to grow exponentially during the forecast period. Major European countries like Germany, France, and the U.K are driving ontogenetic market. On the other hand, Eastern European countries are also contributing a major share to this regional market growth. The U.K is expected to grow at a healthy CAGR in the European ontogenetic market.
The Asia Pacific is the fastest growing ontogenetic market owing to increasing funding for research and development and government initiatives to encourage such research. China and Japan are the major players in this region, while India is emerging as the fastest growing country in ontogenetic market.
However, lack of developed infrastructure, low investment in research and development are likely to slow the Middle East & African ontogenetic market growth.
Key Players
Some of key the players in the ontogenetic market are ANT Neuro (the Netherlands), EMS Handels Gesellschaft mbH (Austria), Natus Medical Incorporated (U.S.), Ontogeny, Inc (U.S.), Symbiotic Devices (Australia), and others.
Report Attribute/Metric |
Details |
Market Size |
USD 1.87 Billion |
CAGR |
3.98% |
Base Year |
2023 |
Forecast Period |
2024-2032 |
Historical Data |
2022 |
Forecast Units |
Value (USD Billion) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered |
Devices, Application, and End User |
Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors |
ANT Neuro (the Netherlands), EMS Handels Gesellschaft mbH (Austria), Natus Medical Incorporated (U.S.), Ontogeny, Inc (U.S.), Symbiotic Devices (Australia), and others |
Key Market Opportunities |
New product launches and R&D Amongst major key Players |
Key Market Drivers |
· Increasing human and animal population· Increasing funding for research |
Ontogenetic Market Highlights: